FOUNDER NOTE · OCTOBER 6, 2026

Why Cheap-to-Truth comes before cheap trials.

A low trial budget is not the same thing as a low cost of learning. If the study cannot answer the decision, or the evidence will not survive regulatory scrutiny, “cheap” can become the most expensive option.

Start with the decision, not the machinery.

Before comparing CRO quotes, countries or site budgets, write down the exact decision the next experiment needs to change. License or walk away? Advance the indication or kill it? Raise capital or stop? If the study cannot change that decision, the design is already carrying dead weight.

Keep the non-negotiables out of the weighted score.

Participant safety, scientific validity, data integrity, rights clarity and regulator usability are not points to trade against cost. They are gates. Once a path clears them, then cost, speed, recruitment, burden and geography can compete.

Optimize the next credible answer.

That may mean a different indication with a shorter endpoint, fewer visits, a more recruitable population, a better jurisdiction, a simpler route of administration, or a smaller experiment that decisively tests the core thesis. The objective is not the cheapest study. It is the lowest time-and-cost to a trustworthy answer.

Make the reasoning inspectable.

The scorecard should expose what it believes. If an asset ranks highly because human safety is strong, the endpoint is objective and the readout is short, those assumptions should be visible. If a ranking collapses when regulatory confidence falls, that should be visible too.

Then earn the right to do more.

That is why the commercial model starts with a bounded Cheap-to-Truth Diligence Sprint. The first product is not “we will run your biotech.” It is “we will pressure-test whether this opportunity deserves deeper work.” Asset sourcing or a virtual-biotech operating structure only makes sense after that.